Topic: biomedical research
Gilead’s senior director of clinical research, Adrian Ray, has moved to Nimbus Therapeutics to become its senior vice president of discovery biology.
BioMarin teamed up with a senior center near its California HQ to turn an environmental cleanup site into new R&D space and housing for the elderly.
Microbiome developer Kaleido Biosciences has raked in $101 million in financing, after coming out of stealth last September with $65 million.
Benchling raised $14.5 million in series B funding to build out its staff and develop its cloud-based data management and collaborative R&D platforms.
Astellas will discontinue work at its R&D subsidiary by March 2019, offering early retirements to 600 staff, as exclusivity losses loom next year.
AstraZeneca has opened its new South San Francisco R&D facility, bundling five sites into a single unit at the heart of California’s biotech cluster.
Galecto Biotech hired Richard Marshall, head of fibrosis discovery at GlaxoSmithKline, to be CMO as it moves into late-phase trials of its IPF drug.
Ironwood plans to split into two independent companies, spinning off some of its R&D work into a yet-unnamed business in the first half of 2019.
GSK executives hint at possible changes in R&D incentives and what another new hire made last week could bring to the pipeline.